Related by context. All words. (Click for frequent words.) 68 Daniel Junius 68 Michael H. Tardugno 68 Steven R. Deitcher 65 Nicole Onetto MD 65 Spiro Rombotis President 64 Dan Passeri Curis 64 Mr. Yves Rosconi 64 Dr. Fahar Merchant 64 Juergen Engel Ph.D. 64 Brian JG Pereira 63 Rolland Yves Mauvernay 63 Joshua Boger Ph.D. 63 refractory colorectal cancer 63 Lisa N. Drakeman 63 Howard H. Pien 63 Georges Gemayel 63 Mark HN Corrigan 63 Safi Bahcall Ph.D. 63 Steve Worland Ph.D. 63 Alton Boynton 62 Clay B. Siegall 62 Donald L. Drakeman 62 J. Donald deBethizy 62 Loïc Maurel MD 62 Dr. Aiping Young 61 Pedro Lichtinger 61 Raymond P. Warrell 61 Neil K. Warma 61 Mark A. Sirgo 61 Blum Cytokinetics 61 Dan Passeri 61 Per Olof Wallström 61 Dr. Randall Yatscoff 61 Bernd R. Seizinger 61 Harry Palmin President 60 Lonnie Moulder 60 James Manuso 60 Adrian Hobden Ph.D. 60 Jeffrey H. Buchalter 60 Christopher J. Schaber 60 Daniel Passeri Curis 60 Burt Adelman 60 Dino Dina 60 obatoclax 60 Keith Katkin AVANIR 60 EndoTAGTM 1 60 Errol De Souza 60 Dr. Horst Zerbe 60 Mark Pykett 60 Francois Nader 60 Jeffrey M. Ostrove 59 Haro Hartounian Ph.D. 59 commented Alexis Borisy 59 Mr. Rosconi 59 NicOx commented 59 Paolo Paoletti MD 59 Dr. Wayne Danter 59 Panzem R NCD 59 Hoyoung Huh MD Ph.D. 59 Mihael Polymeropoulos MD 59 Remi Barbier 59 Christian Itin 58 Steven B. Ratoff 58 Mark Leuchtenberger 58 BLA filing 58 Dr. Raafat Fahim 58 alvespimycin 58 Keith Katkin 58 Elisabeth Lindner CEO 58 Ph.D. Targacept 58 Anker MD Ph.D. 58 IIa trial 58 Gregory A. Demopulos 58 Zami Aberman Chairman 58 Dr. Marlies Sproll 58 Carl Spana Ph.D. 58 Barry D. Quart 58 Mr. Frank Menzler 58 Rajesh C. Shrotriya 58 SNT-MC#/idebenone 58 Neogenix 58 Norbert Bischofberger PhD 58 Onrigin 58 OvaRex R 58 Dr. Von Hoff 58 Mr. Jassawalla 58 Mr. Luc Mainville 58 Virulizin ® 58 Mr. Mordock 57 Carl A. Pelzel 57 Anthony DiTonno President 57 J. Mazzo Ph.D. 57 Murray Tekmira 57 Don Kiepert President 57 Mr. Pierre Laurin 57 Sol J. Barer 57 Æterna Zentaris 57 tanespimycin 57 Christian Itin Ph.D. 57 successfully commercialize Iluvien 57 commented Nicholas Landekic 57 Daniel Von Hoff 57 Safi Bahcall 57 Orville G. Kolterman 57 EMPOWER TM 57 Dr. Ayalew Tefferi 57 Frank Verwiel MD 57 Dr. Yatscoff 57 Jack Lief Arena 57 Dr. Henrich Guntermann 57 Trofex 57 Mr. Bentsur 57 oral picoplatin 57 Ron Bentsur 57 Patrik De Haes 57 ganetespib 57 Jacob Inbar 57 Boyd Soussana 57 Dr. Bassam Damaj 57 Kathy Giusti Founder 56 David Moskowitz GenoMed 56 Chemophase 56 Allovectin 7 56 Lorianne Masuoka MD 56 CINQUIL 56 lumiliximab 56 Hsp# inhibitor tanespimycin 56 tezampanel NGX# 56 Faheem Hasnain 56 Vaughn M. Kailian 56 relapsed SCLC 56 David Aviezer 56 Yuichi Iwaki MD Ph.D. 56 HDL Selective Delipidation 56 Robert L. Chioini 56 CRMD# 56 Igor Gonda Ph.D. 56 Pascal Pfister 56 Camvia 56 Michael Fonstein Ph.D. 56 Iris Loew Friedrich 56 Rosen ViroPharma 56 Avtar Dhillon MD 56 Dr. Arndt Schottelius 56 Kemal Malik 56 Zeb Horowitz 56 ThromboGenics commented 56 Archexin 56 forodesine 56 atacicept 56 Alzhemed TM 56 Vincent Milano ViroPharma 56 Anthony Giovinazzo 56 BNC# 56 Dr. Francesco Bellini 56 Michael V. Novinski 56 Ofer Haviv Evogene 56 ThromboGenics commenting 56 CCR9 antagonist 56 Dr. McHutchison 56 Chang Ahn Rexahn 56 preclinically 56 MAGE A3 ASCI 55 RIGScan CR 55 Tod Woolf Ph.D. 55 compound INCB# 55 J. Schaber PhD 55 Malcolm Skolnick CytoGenix 55 GRN# 55 Philippe Calais 55 Jal S. Jassawalla 55 Radu Leca 55 Quay MD Ph.D. 55 Dr. Isa Odidi 55 Onno van de Stolpe 55 Removab 55 TOLAMBA 55 triphendiol 55 Hedgehog antagonist 55 vosaroxin 55 Yves Rosconi 55 Dr. Kobi Vortman 55 Marc Oczachowski 55 Mr. Fater 55 ganaxolone 55 Dr. Gulfo 55 ThGRF 55 Glenn A. Oclassen 55 SNS# T 55 KIACTA ™ 55 OMAPRO 55 plasma kallikrein inhibitor 55 Ira L. Goldknopf 55 Mitchel Sayare 55 Prestara 55 Rik J Deitsch 55 Dr. Wolfgang Wein 55 Dr. Philip Toleikis 55 Phase #b/#a 55 ELACYT 55 Nicholas Borys 55 Kenneth M. Borow 55 Dr. Tashkin 55 Targretin capsules 55 Paul Laikind 55 samalizumab 55 Michele Garufi Chairman 55 immunosuppressant therapies 55 Sudhir Agrawal D.Phil 55 phase Ib 55 Vincent Mutel CEO 55 Ed Quilty 55 Phase #b/#a clinical 54 thetreatment 54 ENRICH trial 54 vidofludimus 54 INCB# [001] 54 Aplidin 54 Yves Rosconi President 54 NP2 Enkephalin 54 heterozygous FH 54 PROCHYMAL 54 LibiGel ® 54 UPLYSO 54 John C. Ruckdeschel 54 CR# vcMMAE 54 favorable pharmacokinetic profile 54 CMV vaccine 54 Benlysta belimumab 54 Personalized Immunotherapy 54 ZYBRESTAT fosbretabulin 54 orBec 54 ponatinib 54 Xcytrin R 54 Ceflatonin 54 Edward M. Rudnic 54 ACCEDE 54 ZOLINZA 54 AZILECT ® 54 pharmacokinetic PK study 54 HGS# 54 isoform selective 54 Cardio Vascu Grow 54 PANVAC VF 54 MediGene focuses 54 Oliver Sartor 54 Kleanthis G. Xanthopoulos Ph.D. 54 SNT MC# 54 John R. Plachetka 54 BioNumerik 54 eprodisate Fibrillex TM 54 tubulin inhibitor 54 HGS ETR2 54 SUCCEED trial 54 rALLy trial 54 Glen de Vries 54 Dr. Bruno Giannetti 54 ATL/TV# 54 Cloretazine R VNP#M 54 Yvonne Greenstreet 54 Troxatyl 54 Michel Morre DVM 54 Capesaris 54 Mr. Armando Anido 54 H. Kirn 54 Panzem 54 Drew Fromkin President 54 eritoran 54 Mohan Uttarwar 54 commercialize DAVANAT ® 54 brivaracetam 54 oral ridaforolimus 54 Alessandro Riva 54 Laheru 54 deforolimus 54 Tony Milici 54 Hematide ™ 53 enzastaurin 53 Akshay Vaishnaw MD Ph.D. 53 macitentan 53 Cimzia TM 53 epigenetic therapies 53 BrachySil TM 53 Mr. Kriegsman 53 Fx #A 53 Chas Radovich 53 Gerard E. Puorro 53 Fibrillex TM 53 potent suppressor 53 Christopher Anzalone Arrowhead 53 eniluracil 53 ImmunoVEX HSV2 53 pharmacodynamics PD 53 PRECISE Trial 53 RIGScan 53 Robert Motzer MD 53 Elisabeth Lindner 53 Cortria 53 rALLy clinical trial 53 lorvotuzumab mertansine 53 IND submission 53 Greg Wujek 53 Aeolus Pharmaceuticals Announces 53 Fereydoun Firouz 53 torezolid phosphate 53 Mr. Weidong Yin 53 Anavex #-# 53 Brandt Noven 53 Aflibercept 53 David Crockford RegeneRx 53 Bob Butchofsky President 53 John F. Thero 53 Fran DiNuzzo 53 CA9 SCAN 53 AusAm 53 Arranon 53 cMET 53 Robert Siliciano 53 Cinryze ™ 53 Nick Leschly 53 Emer Leahy 53 Abiraterone acetate 53 Cloretazine R 53 inhaled AAT 53 zileuton IV 53 Klaus Schollmeier 53 Mr. Zami Aberman 53 Richard M. Eglen 53 MEND CABG II 53 pediatric acute lymphoblastic 53 Dominique Costantini 53 celgosivir 53 Dendreon Provenge 53 immune modulating 53 Antony Koblish President 53 Allovectin 7 ® 53 Bezielle 53 EP #R 53 R#/MEM # 53 Friedhelm Blobel 53 Dr. Flemming Ornskov 53 Avastin adjuvant 53 maribavir 53 riociguat 53 PXD# 53 EndoTAG TM -1 53 HuMax EGFr 53 Dr. Agarwala 53 QTinno TM 53 Friedhelm Blobel Ph.D. 53 James Sapirstein 53 Bergenstal 53 Christopher L. Coccio 53 IMA# 53 tramiprosate ALZHEMED TM 53 Hsp# inhibition 53 Numoda 53 Kevetrin TM 53 Triapine R 53 receptor tyrosine kinase inhibitor 53 Diamyd r vaccine 53 sargramostim 53 rindopepimut 53 BRAF V# mutation 53 Onconase 53 Hedgehog inhibitor 53 Dr. Fehlings 53 farletuzumab 53 Multiple Ascending Dose 53 fosbretabulin 53 Candace Kendle PharmD 53 Dr. Thomas Ramdahl 52 Zavesca r 52 Eric Van Cutsem 52 MGN# 52 Stephen Ghiglieri 52 Dr. Zelenetz 52 Gregory D. Casciaro 52 Asentar 52 Zevalin consolidation 52 Elocalcitol 52 dexanabinol 52 novel therapeutic antibodies 52 Manja Bouman CEO 52 ANAVEX #-# [001] 52 cystinosis patients 52 Memryte 52 David Spaight 52 Haim Aviv 52 EGS# 52 genomic biomarker 52 Tyrima 52 Dr. Blobel 52 fibrotic disorders 52 Robert L. Bratzler 52 dimebon latrepirdine 52 Joseph K. Belanoff 52 Viramidine 52 HQK 52 H. Willard Flamel 52 Gilles Gagnon 52 Provecta 52 Liposomal Grb 2 52 Jean Luc Bélingard Chairman 52 HCV protease inhibitors 52 patriotism Gration 52 Angiox ® 52 Luc Tanguay 52 Jean Paul Clozel 52 relapsed MCL 52 Zemplar Capsules 52 QLT# 52 ADVEXIN therapy 52 p# inhibitor 52 Randal Mills 52 Asher Chanan Khan 52 OMNARIS HFA 52 mg/m2 cohort 52 Exherin TM 52 alvimopan 52 VALSTAR 52 EchoCRT 52 tafamidis 52 Matthew Emmens 52 antiangiogenic agent 52 C. Warren Olanow 52 ADAGIO study 52 EDEMA3 trial 52 inhaled liposomal ciprofloxacin 52 ThermoDox ® clinical 52 systemic RNAi 52 John E. Niederhuber 52 MDS AML 52 Dr. Michelle Berrey 52 Bernd Seizinger 52 Narachi 52 MyVax ® 52 SinuNase 52 TOCOSOL Paclitaxel 52 Kiadis Pharma 52 antiangiogenic therapy 52 MET amplification 52 TransVax tm 52 Marc Oczachowski EDAP 52 Lixivaptan 52 Phase III ADT 52 Enobia 52 oral methylnaltrexone 52 GALNS 52 ACCLAIM II 52 Plicera 52 Peter Riehl Stellar 52 Plachetka 52 mifamurtide 52 palifosfamide 52 EnVivo 52 Dr. Anil Diwan 52 HuLuc# 52 dacetuzumab 52 RhuDex TM 52 EMPOWER ™ 52 Phase Ib study 52 IRX 2 52 oral FTY# 52 subcutaneous PRO 52 Mr. Tardugno 52 Phase 1a clinical 52 Maurizio Fava MD 52 Cristofanilli 52 recurrent glioblastoma 52 Arno Therapeutics 52 Bioral Amphotericin B 52 Zami Aberman Pluristem 52 Silodosin 52 preclinical pharmacokinetic 52 Garo H. 52 incyclinide 51 JD Avigen 51 BEMA TM Fentanyl 51 vascular disrupting agent 51 Nuvion 51 Pharmacokinetic studies 51 Dr. Maraganore 51 Tomas Puusepp 51 ARIKACE ™ 51 HuMax CD4 51 Dr. Damaj 51 Gord Froehlich President 51 polycythemia vera essential thrombocythemia 51 Catena ® 51 Evoltra 51 stated Michelle Berrey 51 anti leukemic 51 Renaud Beauchesne 51 sapacitabine 51 aEURoeThis 51 Hans Joachim Lohrisch 51 Alfred I. Neugut 51 Ulrich Dauer CEO 51 stated Dominique Costantini 51 budesonide MMX Phase III 51 elacytarabine 51 TEMSO 51 TSXV MFS 51 Bill Forbes Pharm.D 51 Bicifadine 51 SILENOR 51 ularitide 51 Virulizin R 51 recurrent herpes labialis 51 IMC #B 51 XL# SAR# 51 axitinib 51 Sean Roosen President 51 ASCEND HF 51 registrational 51 indibulin 51 Harold Burstein 51 T. Flavin 51 Prof. Krainer 51 refractory systemic ALCL 51 ATL# [001] 51 Kirsten Drejer 51 NPC 1C 51 Anat Cohen Dayag 51 phase IIa clinical 51 INTEGRILIN R eptifibatide Injection 51 HCD# [002] 51 MEPACT 51 Garcia Manero 51 cytokine refractory 51 Pimavanserin 51 MBA EntreMed 51 Matthew Meyerson 51 optimal dosing regimens 51 ONCONASE R 51 website http:/www.celsion.com 51 canakinumab 51 Genz # 51 Spiegelmer ® 51 Prognostic factors 51 Dr. Shrotriya 51 treats acute lymphoblastic 51 Daniel Vasella Chairman 51 phase IIa 51 prolongs survival 51 Pre IND 51 ASONEP 51 Phase #b/#a trial 51 Critchfield MD 51 ZFP Therapeutics 51 ISTODAX 51 Phase IIb III 51 Martin Nicklasson 51 GED aPC 51 clonogenic 51 octreotide implant 51 aerosolized surfactant 51 Stephen M. Simes 51 anidulafungin 51 chemosensitivity 51 Steve Bechman 51 Icatibant 51 Cethrin 51 Dr. Pingpank 51 otelixizumab 51 STRIDE PD 51 E. Magnus Ohman 51 viral kinetics 51 PROVENGE ® 51 CAPHOSOL 51 naronapride 51 Timo Veromaa 51 Dr. Andreas Barner 51 Walter Geldenhuys 51 Cytolin ® 51 ruxolitinib 51 fibrotic disease 51 pivotal bioequivalence 51 sNDA submission 51 GMX# 51 Evoltra ® 51 CHARM Added 51 mGluR5 inhibition 51 chemoresistant 51 James Jiayuan Tong 51 Dr. Gussak 51 Hugh Aird 51 EGFR mutation status 51 Gleevec resistant 51 Aquinox 51 Robert Spanheimer 51 John Maraganore Ph.D. 51 4SC commented 51 Mark Hilz President 51 Chain Intellect 51 Luveniq 51 VIDAZA ® 51 Aerovant 51 rALLy 51 KRAS mutation status 51 DPX Survivac 51 Shai N. Gozani 51 Restanza 51 HuMax TAC 51 Apoptone 51 LibiGel ® testosterone gel 51 rotary VAD 51 AZD# TC 51 poststroke depression 51 AVAX 51 EnzymeRx 51 oral laquinimod 50 Kamada AAT 50 Emezine 50 NEBIDO 50 immunotherapeutic vaccine 50 Somatuline Depot 50 elvucitabine 50 SCOLR Pharma 50 Urocidin 50 PEG SN# 50 BAL# [002] 50 dermatology biopharmaceutical company 50 Phase IIb clinical trials 50 CRD5 50 Amy Abernethy 50 FluoroPharma 50 OHR/AVR# 50 ACCORD Eye 50 PDE# inhibitors 50 liprotamase 50 TRX1 50 trastuzumab DM1 50 GAP #B# 50 Phenoptin 50 Surfaxin LS 50 BRAF inhibitors 50 stated Avtar Dhillon 50 trodusquemine 50 liposomal formulation 50 Oglemilast 50 eTag assays 50 AE# vaccine 50 Tocosol Paclitaxel 50 Neuradiab 50 torsemide ER 50 Philippe Archinard 50 relapsed ALL 50 NSABP C 50 inhibit metastasis 50 TKM PLK1 50 Dr. AF Zerrouk 50 MYLOTARG 50 Dr. Nikolaus Schweickart 50 Dr. Tsengas 50 elotuzumab 50 PRIMO CABG 50 vascular disrupting agents 50 initiate Phase 1b 50 Carotid endarterectomy 50 SomatoKine 50 PROSTVAC TM 50 DCCR 50 orally administered inhibitor 50 Pseudomonas aeruginosa infections 50 Eckard Weber 50 isavuconazole 50 ProSavin 50 cannabinor 50 ispinesib administered 50 Gil Mor 50 Phase III HEAT 50 midstage clinical 50 Andrin Oswald CEO 50 TBC# 50 Carl LeBel 50 PRTX 50 tramiprosate Alzhemed TM 50 PRESEPT 50 Insegia 50 selective modulator 50 biologic plausibility 50 Raj Mohinder Gurm 50 DSMB recommendation 50 registrational trial 50 TOCOSOL 50 GLP toxicology studies 50 hoax Alderden 50 Dacogen injection 50 TYSABRI natalizumab 50 nalbuphine ER 50 JAK inhibitor 50 Altastaph 50 MET inhibitor 50 triglyceride lowering 50 RhuDex 50 ZEVALIN ® 50 APEX AMI 50 Bresalier 50 Cethromycin 50 subsidiaries visit http:/www.apricusbio.com 50 huC# DM4 50 FOLOTYN ® 50 Potelligent Technology 50 Phase 2a trial 50 Sanjay Bhanot 50 SonoLysis 50 OraTest R 50 novel histone deacetylase 50 Adventrx 50 BenzEFoam 50 Sphingomab TM 50 pharmacological chaperone 50 Hedgehog Pathway Inhibitor 50 Frank Baldino Jr. 50 DELEX 50 REGEN trial 50 ICON7 50 novel oral anticoagulant 50 CONBRIZA 50 Viprinex 50 Ele Ferrannini 50 CURE AF 50 MAA submission 50 ENMD # 50 Dr. Manuso 50 histamine dihydrochloride 50 AeroLEF TM 50 Canvaxin 50 Fibrillex 50 evaluating Actimmune 50 CCX# B 50 talabostat 50 OnDose TM 50 Oracea TM 50 Simon Sturge 50 talactoferrin 50 Alan Menter 50 refractory CLL 50 ASG 5ME 50 DDP# 50 InteKrin 50 ICA # 50 Panzem ® 50 CIMZIA TM 50 Bradbury Amylin 50 haematological cancers 50 Toraymyxin TM 50 AERx iDMS 50 KRYSTEXXA TM pegloticase 50 Novolimus 50 imexon 50 CINTREDEKIN BESUDOTOX 50 therapeutic monoclonal antibody 50 faropenem medoxomil 50 tramiprosate 50 OvaRex 50 Ceplene histamine dihydrochloride 50 TroVax ® 50 Vitaxin 50 ARISE Phase III 50 TSX VENTURE CPQ 49 adrenergic regulation 49 Guanilib 49 leading oral taxane 49 OncoVEX 49 Vidofludimus 49 immune modulatory 49 NV1FGF 49 MERLIN TIMI 49 mTOR inhibition 49 initiated Phase Ib 49 Gary Ghiselli 49 Ampio 49 omacetaxine mepesuccinate 49 SPARLON 49 Phase IIb trials 49 JAK2 inhibitor 49 ACTEMRA TM 49 Telatinib 49 Lung Rx 49 OraTest 49 mCRPC 49 oral rivaroxaban 49 Sylvie Gregoire President 49 ocrelizumab 49 Ketotransdel 49 HIV coinfected 49 statistically significant efficacy 49 Lisofylline 49 Firazyr 49 Jean Gabriel Pérès 49 GFT# 49 DACH platinum 49 Steven Nichtberger MD 49 PRECISE trial 49 Gary Morsch 49 Ms. Zhilin Li 49 LibiGel Phase III 49 Traficet EN 49 AZILECT R 49 PSN# [002] 49 Walter Witoshkin 49 pharmacodynamic PD 49 tecarfarin 49 dermatology biopharmaceutical 49 favorable tolerability 49 oxidative stress induction 49 brentuximab vedotin SGN 49 Aviptadil 49 PIX# trial 49 TRO# 49 Mr. Xiangzhi Chen 49 midstage trials 49 confirmatory pivotal 49 Exelixis XL# 49 NLX P# 49 PI3K/Akt pathway inhibitor 49 Thorough QT Study 49 Phase III confirmatory 49 MEK inhibitor RDEA# 49 Velac 49 neuroinflammatory 49 PhosLo 49 TransVax ™ 49 BRAF V#E mutation 49 preclinical efficacy 49 docetaxel emulsion 49 TransVax 49 Project Boveri Find 49 romidepsin 49 RH1 49 EOquin 49 Uvidem 49 Arthur P. Bollon 49 CINOD 49 Q#IR 49 André Michel Ballester 49 Etubics 49 B. Lynne Parshall 49 dasatinib Sprycel 49 Hematide ™ peginesatide 49 MacuSight 49 Dr. Bahcall 49 palifermin 49 IL-#/# 49 Rachel Ballard Barbash 49 Harold Van Wart 49 George D. Yancopoulos 49 interferon beta therapy 49 Arginox 49 Anturol TM 49 Civacir 49 Wayne Koff 49 Angiocept 49 Sijmen de Vries 49 Ronan O'Caoimh CEO 49 Daniel H. Movens 49 ORBIT II 49 Atiprimod 49 Randomized clinical trials 49 YONDELIS 49 Thiovir 49 Thorough QT 49 INT# [002] 49 StemEx R 49 eprotirome 49 darinaparsin Zinapar TM 49 bortezomib Velcade 49 TRISENOX 49 TACI Ig 49 histone deacetylase HDAC 49 OvaRex ® MAb 49 LidoPAIN SP 49 VIDAZA azacitidine 49 L BLP# 49 rasagiline tablets 49 JAK#/JAK# inhibitor CYT# 49 PROMACTA 49 Ablynx commented 49 pradefovir 49 orphan medicinal product 49 HepeX B 49 non metastatic osteosarcoma 49 XmAb# 49 phase IIb trial 49 Zingo TM 49 RhuDex ® 49 A3 adenosine receptor 49 clevidipine 49 vismodegib 49 Raymond E. Dellerba 49 Urocortin 2 49 PHX# 49 K ras mutations 49 PSMA ADC 49 Dr. Ihor Gussak 49 Dr. Scangos 49 dose escalation phase 49 kinase inhibition 49 Mr. Jinsheng Ren 49 somatostatin receptor 49 potent antiproliferative 49 Egrifta 49 oral ghrelin agonist 49 faropenem 49 Santhera 49 MYTHOS trial 49 Aurora kinase inhibitor 49 Viprinex TM 49 unique alkylating agent 48 JAK inhibitors 48 Sayan Navaratnam 48 Tarvacin Anti Cancer 48 phase IIb clinical 48 recombinant PSMA vaccine 48 IMPACT IMmunotherapy 48 JAK#/JAK# 48 seasonal influenza VLP vaccine 48 budesonide foam 48 Phase IIB 48 Trofex TM 48 Martin Nicklasson CEO 48 DermaVir Patch 48 Pyridorin 48 Neuromodulation System 48 URG# 48 Myriad Flurizan 48 small molecule tyrosine 48 Modrenal 48 omacetaxine 48 Technosphere Insulin 48 Endoscopic Ablation System 48 myeloproliferative diseases 48 SinuNase ™ 48 Ceflatonin R 48 Tovaxin ® 48 Skip Cummins Cyberonics 48 C1 INH 48 PathFinderTG 48 clonidine hydrochloride 48 Nasdaq SGEN 48 OvaRex MAb 48 Aegera 48 EGFr humanized monoclonal antibody 48 evaluating Nexavar 48 Symadex 48 Prosaptide 48 Bellicum 48 Can Fite 48 Richard J. Meelia 48 PS# [001] 48 TKM ApoB 48 Qinghuan Wu 48 equivocal appendicitis 48 Julie Lee Harrs 48 Weimbs 48 Damian Marron 48 trastuzumab DM1 T DM1 48 confirmatory clinical 48 uric acid lowering 48 ASSERT trial 48 Dynogen 48 opioid bowel dysfunction 48 Mr. Melnuk 48 Bellicum Pharmaceuticals Inc. 48 antidepressant efficacy 48 dalbavancin 48 SYGNIS 48 Adnectin 48 Bioaccelerate compounds under 48 Avastin Erbitux 48 Maddon MD Ph.D. 48 R roscovitine 48 REOPRO 48 CIP TRAMADOL ER 48 Posiphen TM 48 Roberto Bolli 48 ® natalizumab 48 Tony Wyss Coray 48 MetMAb 48 THALOMID 48 GLYX 48 Pantginis 48 granted Ortec 48 ACTIVE W 48 tasimelteon 48 CRACM 48 adenosine deaminase 48 AA Amyloidosis 48 Nasdaq SGMO announced 48 dose proportionality 48 Akt inhibitor 48 ILLUMINATE 48 SURFAXIN r 48 3 registrational trial 48 VITAL Trial 48 imatinib therapy